Equities

Vir Biotechnology Inc

VIR:NSQ

Vir Biotechnology Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)9.60
  • Today's Change-0.17 / -1.74%
  • Shares traded940.69k
  • 1 Year change+11.76%
  • Beta0.5400
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,5222,402708
Total Receivables, Net--0773
Total Inventory------
Prepaid expenses5310473
Other current assets, total13138.59
Total current assets1,5882,5191,563
Property, plant & equipment, net167188130
Goodwill, net171717
Intangibles, net233333
Long term investments10524201
Note receivable - long term------
Other long term assets12152.78
Total assets1,9192,8021,954
LIABILITIES
Accounts payable6.336.426.52
Accrued expenses104489142
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total6516193
Total current liabilities175511341
Total long term debt000
Total debt000
Deferred income tax--3.2518
Minority interest------
Other liabilities, total153210163
Total liabilities329724522
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital1,8291,7101,572
Retained earnings (accumulated deficit)(238)377(139)
Treasury stock - common------
Unrealized gain (loss)(0.82)(9.12)(1.1)
Other equity, total------
Total equity1,5902,0781,432
Total liabilities & shareholders' equity1,9192,8021,954
Total common shares outstanding135133131
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.